Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors

Critical Reviews in Oncology/Hematology

Volumn 53, Issue 2, 2005, Pages 125-131

  Minisini, A ^a   Spazzapan, S ^b   Crivellari, D ^b   Aapro, M ^c   Biganzoli, L ^a,d  

^a JULES BORDET INSTITUTE   (Belgium)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c CLINIQUE DE GENOLIER   (Switzerland)

^d Prato Hospital   (Italy)

Author keywords

Breast cancer; Chemotherapy; Elderly; Febrile nutropenia; G CSF

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; COLONY STIMULATING FACTOR; DOXORUBICIN; EPIRUBICIN;

AGED; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG SAFETY; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL COST; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; REVIEW; STANDARD;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLONY-STIMULATING FACTORS; FEMALE; FEVER; HOSPITALIZATION; HUMANS; INFECTION; NEUTROPENIA; RETROSPECTIVE STUDIES;

EID: 12344264783     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.11.003     Document Type: Review

References (38)

1. J. Ferlay, F. Bray, R. Sankila, and D.M. Parkin EUCAN cancer incidence, mortality and prevalence in the European Union IARC cancer base 2000 IARC Press Lyon
2. J.H. Lewis, M.L. Kilgore, and D.P. Goldman Participation of patients 65 years of age or older in cancer clinical trials J Clin Oncol 21 7 2003 1383 1389
3. L. Balducci, and M. Extermann Management of cancer in the older person: a practical approach Oncologist 5 2000 224 237
4. L. Balducci, C.L. Hardy, and G.H. Lyman Hemopoietic reserve in the older cancer patient: clinical and economic considerations Cancer Control 7 6 2000 539 547
5. N.K. Ibrahim, A.U. Buzdar, L. Asmar, R.L. Theriault, and G.N. Hortobagyi Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up Ann Oncol 11 2000 1597 1601
6. E.C. Dees, S. O'Reilly, and S.N. Goodman A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer Cancer Invest 18 6 2000 521 529
7. D. Crivellari, M. Bonetti, and M. Castiglione-Gersch Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study roup trial VII J Clin Oncol 18 7 2000 1412 1422
8. J. Zalcberg, D. Kerr, L. Seymour, and M. Palmer Haemathological and non-haemathological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number Eur J Cancer 34 12 1998 1871 1875
9. L. Balducci Geriatric Oncology Crit Rev Oncol Hematol 46 2003 211 220
10. G.H. Lyman, J. Crawford, D. Dale, H. Chen, Y. Agboola, and L. Lininger Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy Proc Am Soc Clin Oncol 20 2001 394a [abstract 1571]
11. L. Balducci, and G.H. Lyman Patients aged ≥70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderatly toxic chemotherapy J Clin Oncol 19 2001 1583 1585 [letter]
12. G.H. Lyman, N.M. Kuderer, and B. Djulbegovic Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis Am J Med 112 2002 406 411
13. L. Balducci, and G. Yates Genreal guidelines for the management of older patients with cancer Oncology 14 2000 221 227
14. L. Repetto, L. Biganzoli, and C.H. Kohene EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer Eur J Cancer 39 2003 2264 2272
15. V.G. Kaklamani, and W.J. Gradishar Epirubicin versus doxorubicin: which anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 4 Suppl. 1 2003 S26 S33
16. P.L. Zinzani Complications of cytotoxic chemotherapy in older patients: focus on myelotoxicity in lymphomas Crit Rev Oncol Hematol 48S 2003 S27 S31
17. G. Salles, J. Bienvenu, and Y. Bastion Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients Br J Haematol 93 1996 352 359
18. H. Kato, T. Kinoshita, and S. Suzuki Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma Leuk Lymphoma 29 1998 71 79
19. R. Eppelbaum, N. Haim, and M. Ben-Shahar Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma Isr J Med Sci 24 1988 533 538
20. L.W. Kwak, J. Halpern, and R.A. Olshen Prognostic significance of actual dose intensity in diffuse large-cell lymphoma:results of a tree-structured survival analysis J Clin Oncol 8 1990 963 977
21. E. Lepage, C. Gisselbrecht, and C. Haison Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application of the LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomas de l'Adult) Ann Oncol 4 1993 651 656
22. D.R. Budman, D.A. Berry, and C.T. Cirrincione Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B J Natl Cancer Inst 90 1998 1205 1211
23. W.C. Wood, D.R. Budman, and A.H. Korzun Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N Engl J Med 330 1994 1253 1259
24. M.N. Levine, V.H. Branwell, and K.I. Pritchard Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 16 1998 2651 2658
25. French Adjuvant Study Group Benefit of high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial J Clin Oncol 19 2001 602 609
26. R. Paridaens, L. Biganzoli, and P. Bruning Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized Study with cross-over J Clin Oncol 18 2000 724 733
27. G.W. Sledge, D. Neuberg, and P. Bernardo Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 2003 588 592
28. G.H. Lyman, C.G. Lyman, R.A. Sanderson, and L. Balducci Decision analysis of hemopoietic growth factor use in patients receiving cancer chemotherapy J Natl Cancer Inst 85 1993 488 493
29. G.H. Lyman, N. Kuderer, J. Greene, and L. Balducci The economics of febrile neutropenia: implications for the use of colony-stimulating factors Eur J Cancer 34 12 1998 1857 1864
30. Repertoire Commente des medicaments. Centre Belge d'Information pharmacotherapeutique. Brussels, Belgium, 2003.
31. NCCN Clinical Practice Guidelines in Oncology; v.1.2002. Fever and Neutropenia. www.nccn.com.
32. J. Klastersky, M. Paesmans, and E.B. Rubenstein The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients J Clin Oncol 18 2000 3038 3051
33. M. Exterman, H. Chen, and A.B. Cantor Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study Eur J Cancer 38 2002 1466 1473
34. J.H. Silber, M. Fridman, R.S. DiPaola, M.H. Erder, M.V. Pauly, and K.R. Fox First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy J Clin Oncol 16 1998 1392 2400
35. E. Rivera, M.H. Erder, M. Fridman, D. Frye, and G.N. Hortobagyi First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study Breats Cancer Res 5 2003 R114 R120
36. Z. Rahman, L. Esparza-Guerra, H.-Y. Yap, G. Fraschini, G. Bodey, and G. Hortobagyi Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy Cancer 79 1997 1150 1157
37. L. Repetto, L. Fratino, and R.A. Audisio Comprehensive geriatric assessment adds information to eastern cooperative group performance status in elderly cancer patients: an Italian group for geriatric oncology study J Clin Oncol 20 2002 494 502
38. V. Zagonel, L. Fratino, and P. Piselli The comprehensive geriatric assessment (CGA) predicts mortality among elderly cancer patients (ECP) Proc Am Soc Clin Oncol 21 2002 365a [abstract 1458]